Simulations Plus Inc (SLP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Simulations Plus Inc (SLP) has a cash flow conversion efficiency ratio of 0.074x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.25 Million) by net assets ($139.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Simulations Plus Inc market cap and net worth for the company's overall valuation and market capitalisation.
Simulations Plus Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Simulations Plus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Simulations Plus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Simulations Plus Inc ranked by their cash flow conversion efficiency. Explore Simulations Plus Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
Shandong Shanda Oumasoft CO.LTD.
SHE:301185
|
N/A |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
0.022x |
|
Future Generation Australia Ltd
AU:FGX
|
0.095x |
|
GWA Group Ltd
AU:GWA
|
0.116x |
|
Joy Kie Corporation Limited.
SHE:300994
|
0.052x |
|
China United Travel Co Ltd
SHG:600358
|
0.144x |
|
Pekat Group Bhd
KLSE:0233
|
0.033x |
Annual Cash Flow Conversion Efficiency for Simulations Plus Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Simulations Plus Inc from 1996 to 2025. View Simulations Plus Inc (SLP) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $124.80 Million | $18.13 Million | 0.145x | +98.92% |
| 2024-08-31 | $182.43 Million | $13.32 Million | 0.073x | -43.20% |
| 2023-08-31 | $170.03 Million | $21.86 Million | 0.129x | +28.00% |
| 2022-08-31 | $178.25 Million | $17.90 Million | 0.100x | -13.30% |
| 2021-08-31 | $165.78 Million | $19.20 Million | 0.116x | +65.64% |
| 2020-08-31 | $156.04 Million | $10.91 Million | 0.070x | -77.36% |
| 2019-08-31 | $37.68 Million | $11.64 Million | 0.309x | +6.16% |
| 2018-08-31 | $31.92 Million | $9.29 Million | 0.291x | +9.15% |
| 2017-08-31 | $25.80 Million | $6.88 Million | 0.267x | +11.89% |
| 2016-08-31 | $22.73 Million | $5.42 Million | 0.238x | -34.79% |
| 2015-08-31 | $19.53 Million | $7.13 Million | 0.365x | +6.26% |
| 2014-08-31 | $15.44 Million | $5.31 Million | 0.344x | +91.08% |
| 2013-08-31 | $14.24 Million | $2.56 Million | 0.180x | -28.00% |
| 2012-08-31 | $15.14 Million | $3.78 Million | 0.250x | +0.29% |
| 2011-08-31 | $14.04 Million | $3.50 Million | 0.249x | +11.86% |
| 2010-08-31 | $13.05 Million | $2.91 Million | 0.223x | -5.50% |
| 2009-08-31 | $10.57 Million | $2.49 Million | 0.236x | -5.64% |
| 2008-08-31 | $9.92 Million | $2.48 Million | 0.250x | -35.39% |
| 2007-08-31 | $7.66 Million | $2.96 Million | 0.387x | +90.98% |
| 2006-08-31 | $5.67 Million | $1.15 Million | 0.202x | -31.56% |
| 2005-08-31 | $4.86 Million | $1.44 Million | 0.296x | +128.72% |
| 2004-08-31 | $4.45 Million | $575.05K | 0.129x | -21.73% |
| 2003-08-31 | $3.28 Million | $541.85K | 0.165x | +14.24% |
| 2002-08-31 | $767.88K | $111.07K | 0.145x | -85.99% |
| 2001-08-31 | $282.97K | $292.10K | 1.032x | +239.14% |
| 2000-08-31 | $486.07K | $147.95K | 0.304x | +152.85% |
| 1999-08-31 | $740.66K | $89.16K | 0.120x | +111.96% |
| 1998-08-31 | $1.28 Million | $-1.29 Million | -1.007x | -141.11% |
| 1997-08-31 | $3.35 Million | $-1.40 Million | -0.418x | -183.51% |
| 1996-08-31 | $200.00K | $100.00K | 0.500x | -- |
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans… Read more